B. Riley downgraded Enovix from buy to neutral and significantly cut its price target from $9 to $2 following disappointing Q3 2026 results and revised strategic priorities. The downgrade was primarily driven by Enovix's reported revenue of $11.04 million and Q4 revenue guidance that missed analyst consensus, indicating a significant negative shift in the company's outlook.
B. Riley downgraded Enovix (ENVX) from 'buy' to 'neutral' and slashed its price target from $9 to $2 after the company's Q3 2026 earnings report. The downgrade was a direct response to Enovix's reported revenue of $11.04 million and Q4 revenue guidance that fell below analyst expectations, coupled with revised strategic priorities. This analyst action signals a significant loss of confidence in Enovix's near-term prospects and growth trajectory, impacting current shareholders and potential investors. In the short term, the stock is likely to experience downward pressure due to the negative analyst sentiment and reduced price target. Long-term implications depend on Enovix's ability to execute its revised strategic priorities and improve financial performance, but the immediate outlook is challenging. For traders, the key risk is further downside given the substantial price target reduction and negative guidance.